chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: COVID19
Symptoms: Anxiety, Brain injury
Clinical narrative: BRAIN INJURY; KIND OF ANXIOUS; This spontaneous report received from a male patient of unspecified age, reporting self. Initial information was processed with additional information received on 04-MAR-2024. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (dose series: 1) (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for covid-19 prophylaxis. No concomitant medications were reported. On an unspecified date, the patient experienced brain injury, (dose series: 1) and kind of anxious (dose series: 1). The patient stated that he took the Janssen Covid-19 vaccine before and during the call, the patient stated he was kind of anxious and have a brain injury, so he tend to not wait long enough for people to respond to him. The patient did not mention if he started having anxiety and brain injury prior to or after taking the Janssen Covid-19 vaccine. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the kind of anxious and brain injury was not reported. This report was serious (Other Medically Important Condition). This report was associated with a product quality complaint: 90000315581, 90000315595 and 90000315596. The suspected product quality complaint (90000315595 and 90000315596) has been confirmed to be this customer preference case has been assessed and does not represent a product quality complaint. the disposition and root cause determination were documented properly. based on the PQC evaluation/investigation performed. This record (90000315581) is identified as a duplicate/follow up to record 90000315596 which is a customer preference report regarding the vaccine. Records have been cross referenced as appropriate. Approval to void this duplicate complaint report.; Sender's Comments: Brain injury. Insufficient information is available to make a causality assessment. Therefore, this event is considered unclassifiable.
Sex: U
Vaccine: COVID19
Symptoms: Cough
Clinical narrative: Uptoday I still have some coughing; This spontaneous case was reported by a patient and describes the occurrence of COUGH (Uptoday I still have some coughing) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) (batch no. 8057413) for COVID-19 prophylaxis.     The patient's past medical history included COVID-19 (Patient was not sure, got COVID after vaccination (Months later)). Previously administered products included for Product used for unknown indication: PFIZER BIONTECH COVID-19 VACCINE (Dose 1, at 10:00, Batch No.- EW0158) on 01-May-2021, PFIZER BIONTECH COVID-19 VACCINE (Dose 2, at 09:30, Batch No.- EW0172) on 22-May-2021, PFIZER BIONTECH COVID-19 VACCINE (Dose 3, at 13:15 and Batch No.- FF2593) on 16-Dec-2021; for COVID-19: Paxlovid (Batch no.- GL3909, Expiry date - 12/2023, Route - Oral, 300mg/100mg twice daily, Duration of treatment - 5 days and Discontinued). Past adverse reactions to the above products included No adverse event with PFIZER BIONTECH COVID-19 VACCINE, PFIZER BIONTECH COVID-19 VACCINE and PFIZER BIONTECH COVID-19 VACCINE; and Taste bitter with Paxlovid. Family history included Diabetes and Blood pressure high.    On 10-Feb-2024 at 11:00 AM, the patient received fourth dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. On an unknown date, the patient experienced COUGH (Uptoday I still have some coughing). At the time of the report, COUGH (Uptoday I still have some coughing) had not resolved.            No concomitant medication was reported.  Reportedly, until the reporting day, patient still had some coughing.  No treatment information was provided.
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Chills, Fatigue
Clinical narrative: 24 hours after the vaccinations she had bad fatigue, no energy at all, and chills; 24 hours after the vaccinations she had bad fatigue, no energy at all, and chills; 24 hours after the vaccinations she had bad fatigue, no energy at all, and chills; This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (24 hours after the vaccinations she had bad fatigue, no energy at all, and chills), FATIGUE (24 hours after the vaccinations she had bad fatigue, no energy at all, and chills) and CHILLS (24 hours after the vaccinations she had bad fatigue, no energy at all, and chills) in an adult female patient who received SPIKEVAX NOS (SPIKEVAX NOS) for Vaccination.     The patient's past medical history included Pre-eclampsia and Nerve pain. Concurrent medical conditions included Multiple sclerosis relapse, Sleepy (Gabapentin makes her sleepy) and Blood pressure high. Concomitant products included GABAPENTIN, HYDROCHLOROTHIAZIDE, TRIAMTERENE (MAXZIDE) and BACLOFEN for an unknown indication.    On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (unknown route) 1 dosage form. On an unknown date, the patient experienced ASTHENIA (24 hours after the vaccinations she had bad fatigue, no energy at all, and chills), FATIGUE (24 hours after the vaccinations she had bad fatigue, no energy at all, and chills) and CHILLS (24 hours after the vaccinations she had bad fatigue, no energy at all, and chills). At the time of the report, ASTHENIA (24 hours after the vaccinations she had bad fatigue, no energy at all, and chills), FATIGUE (24 hours after the vaccinations she had bad fatigue, no energy at all, and chills) and CHILLS (24 hours after the vaccinations she had bad fatigue, no energy at all, and chills) had resolved.        The action taken with SPIKEVAX NOS (SPIKEVAX NOS) (Unknown) was unknown.       No treatment medications was provided.
Age: 18.0
Sex: F
Vaccine: MENB, MNQ
Symptoms: Erythema, Headache, Inappropriate schedule of product administration, Pain in extremity, Peripheral swelling
Clinical narrative: Full left arm redness; Full left arm swelling; Full left arm, it's painful to touch; Headache; Low grade fever; First dose on 16Mar2022/Second dose on 21Feb2024; This is a spontaneous report and received from Other HCPs from medical information team.  An 18-year-old female patient received meningococcal group b Rlp2086 (TRUMENBA), on 21Feb2024 at 12:20 as dose 2, 0.5 ml single (Lot number: GH4067, Expiration Date: 30Aug2025) at the age of 18 years intramuscular, in left arm for immunisation; meningococcal vaccine a/c/y/w conj (tet tox) (MENQUADFI), on 21Feb2024 as dose number unknown, single (Lot number: U7938AA, Expiration Date: 28Feb2026) intramuscular for immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). Concomitant medication(s) included: FLOVENT taken for asthma. Vaccination history included: trumenba (Dose 1, Lot Number: DW2999, Route, Anatomical Location: IM, Right Deltoid), administration date: 16Mar2022, when the patient was 16-year-old, for Immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 21Feb2024, outcome "unknown", described as "First dose on 16Mar2022/Second dose on 21Feb2024"; ERYTHEMA (non-serious) with onset 22Feb2024, outcome "unknown", described as "Full left arm redness"; PERIPHERAL SWELLING (non-serious) with onset 22Feb2024, outcome "unknown", described as "Full left arm swelling"; PAIN IN EXTREMITY (non-serious) with onset 22Feb2024, outcome "unknown", described as "Full left arm, it's painful to touch"; HEADACHE (non-serious) with onset 22Feb2024, outcome "unknown"; PYREXIA (non-serious) with onset 22Feb2024, outcome "recovered" (2024), described as "Low grade fever". The events "full left arm redness", "full left arm swelling", "full left arm, it's painful to touch", "headache" and "low grade fever" required physician office visit. Therapeutic measures were taken as a result of pyrexia. Additional information: patient experienced full left arm redness, swelling, and it's painful to touch. The area of arm is like 5x6 inches to 5x6 inches that is red. Patient also had headache. Patient also had a low grade fever, onset time provided as in the evening. Treatment: Rotate between Tylenol and Ibuprofen. Also taking Benadryl. No Prior Vaccinations within 4 weeks.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400056401 Same product/event, different patient;US-PFIZER INC-202400056396 Same reporter/drug, different patient, similar event;
Age: 18.0
Sex: F
Vaccine: MENB, MNQ
Symptoms: Pyrexia, Tenderness
Clinical narrative: Full left arm redness; Full left arm swelling; Full left arm, it's painful to touch; Headache; Low grade fever; First dose on 16Mar2022/Second dose on 21Feb2024; This is a spontaneous report and received from Other HCPs from medical information team.  An 18-year-old female patient received meningococcal group b Rlp2086 (TRUMENBA), on 21Feb2024 at 12:20 as dose 2, 0.5 ml single (Lot number: GH4067, Expiration Date: 30Aug2025) at the age of 18 years intramuscular, in left arm for immunisation; meningococcal vaccine a/c/y/w conj (tet tox) (MENQUADFI), on 21Feb2024 as dose number unknown, single (Lot number: U7938AA, Expiration Date: 28Feb2026) intramuscular for immunisation. The patient's relevant medical history included: "Asthma" (unspecified if ongoing). Concomitant medication(s) included: FLOVENT taken for asthma. Vaccination history included: trumenba (Dose 1, Lot Number: DW2999, Route, Anatomical Location: IM, Right Deltoid), administration date: 16Mar2022, when the patient was 16-year-old, for Immunization. The following information was reported: INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 21Feb2024, outcome "unknown", described as "First dose on 16Mar2022/Second dose on 21Feb2024"; ERYTHEMA (non-serious) with onset 22Feb2024, outcome "unknown", described as "Full left arm redness"; PERIPHERAL SWELLING (non-serious) with onset 22Feb2024, outcome "unknown", described as "Full left arm swelling"; PAIN IN EXTREMITY (non-serious) with onset 22Feb2024, outcome "unknown", described as "Full left arm, it's painful to touch"; HEADACHE (non-serious) with onset 22Feb2024, outcome "unknown"; PYREXIA (non-serious) with onset 22Feb2024, outcome "recovered" (2024), described as "Low grade fever". The events "full left arm redness", "full left arm swelling", "full left arm, it's painful to touch", "headache" and "low grade fever" required physician office visit. Therapeutic measures were taken as a result of pyrexia. Additional information: patient experienced full left arm redness, swelling, and it's painful to touch. The area of arm is like 5x6 inches to 5x6 inches that is red. Patient also had headache. Patient also had a low grade fever, onset time provided as in the evening. Treatment: Rotate between Tylenol and Ibuprofen. Also taking Benadryl. No Prior Vaccinations within 4 weeks.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400056401 Same product/event, different patient;US-PFIZER INC-202400056396 Same reporter/drug, different patient, similar event;
Sex: F
Vaccine: COVID19
Symptoms: Influenza, Near death experience
Clinical narrative: severe flu; almost dies; This is a spontaneous report received from a Consumer or other non HCP from medical information team.  A female patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: INFLUENZA (hospitalization), outcome "unknown", described as "severe flu"; NEAR DEATH EXPERIENCE (medically significant), outcome "unknown", described as "almost dies". Clinical course: The reporter (husband) mentioned that his wife has got the latest Comirnaty vaccine and he has got 4 Pfizer BioNTech COVID-19 vaccines. His wife came down with severe flu and almost dies, she had to be hospitalized and he also got the flu from his wife but a mild case. The reporter mentined he has not taken the latest Pfizer COVID vaccine because some of his colleagues that are MDs have told him about side effects their patients have experienced.   No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Sex: F
Vaccine: PNC20
Symptoms: Cellulitis, Erythema, Injection site pain, Swelling
Clinical narrative: cellulitis; erythema; swelling; pain in the left arm from the shoulder to the inner elbow area; pain in the left arm from the shoulder to the inner elbow area; This is a spontaneous report received from an Other HCP.  A female patient (not pregnant) received pneumococcal 20-val conj vac (dipht CRM197 protein) (PREVNAR 20), on 01Mar2024 at 09:30 as dose number unknown, single (Lot number: HG7739), in left deltoid for immunisation. The patient's relevant medical history included: "Hyperlipidemia" (unspecified if ongoing); "Vitamin D Deficiency" (unspecified if ongoing); "GERD" (unspecified if ongoing); "Breast Cancer" (unspecified if ongoing); "Osteopenia" (unspecified if ongoing); "Eczema" (unspecified if ongoing); "Known allergies: Oxycodone and Sulfa Drugs" (unspecified if ongoing). There were no concomitant medications. The following information was reported: CELLULITIS (non-serious) with onset 02Mar2024, outcome "not recovered"; ERYTHEMA (non-serious) with onset 02Mar2024, outcome "not recovered"; PAIN IN EXTREMITY (non-serious), ARTHRALGIA (non-serious) all with onset 02Mar2024, outcome "not recovered" and all described as "pain in the left arm from the shoulder to the inner elbow area"; SWELLING (non-serious) with onset 02Mar2024, outcome "not recovered". The events "cellulitis", "erythema", "swelling" and "pain in the left arm from the shoulder to the inner elbow area" required physician office visit. Therapeutic measures were taken as a result of cellulitis, erythema, swelling, pain in extremity, arthralgia.  Causality for "cellulitis", "erythema", "swelling" and "pain in the left arm from the shoulder to the inner elbow area" was determined associated to device constituent of pneumococcal 20-val conj vac (dipht CRM197 protein) (malfunction).  Additional information: Treatment included Medrol Dosepak and Keflex. No other vaccine same date. No other vaccine in four weeks. Patient presented to clinic today 05Mar24 with severe localized reaction to include cellulitis, erythema, swelling, and pain in the left arm from the shoulder to the inner elbow area.
Age: 76.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: COVID-19; COVID-19; This is a spontaneous report received from a Consumer or other non HCP.  A 77-year-old male patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 18Oct2023 at 12:00 as dose 1, single (Batch/Lot number: unknown) at the age of 76 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Hypertension" (unspecified if ongoing); "Penicillin allergy" (unspecified if ongoing). Concomitant medication(s) included: LISINOPRIL, start date: 04Oct2023. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 2, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 3, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 4, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 5, MANUFACTURER UNKNOWN), for COVID-19 immunization; Covid-19 vaccine (DOSE 6, MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset Feb2024, outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of vaccination failure, covid-19 (Anti-viral from 26Feb2024 to 01Mar2024).  The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400058413 same patient, different drug/event;
Sex: F
Vaccine: PNC20
Symptoms: Pain in extremity, Shoulder injury related to vaccine administration
Clinical narrative: "SIRVA" arm pain from an injection 1 year ago pcv20; This is a spontaneous report received from an Other HCP from a sales representative.  A female patient received pneumococcal 20-val conj vac (dipht CRM197 protein) (PNEUMOCOCCAL 20-VAL CONJ VAC (DIPHT CRM197 PROTEIN)), in 2023 as dose 1, single (Batch/Lot number: unknown), in arm for immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SHOULDER INJURY RELATED TO VACCINE ADMINISTRATION (non-serious), outcome "unknown", described as ""SIRVA" arm pain from an injection 1 year ago pcv20". It was unknown if therapeutic measures were taken as a result of shoulder injury related to vaccine administration.  Additional information: Patient complained about "SIRVA" arm pain from an injection 1 year ago.     No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: COVID-19; COVID-19; This is a spontaneous report received from a nurse.  A 30-year-old female patient (not pregnant) received BNT162B2 OMI XBB.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: COVID-19 vaccine (DOSE 1 and 2; MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". Therapeutic measures were taken as a result of events which included nirmatrelvir/ ritonavir (PAXLOVID) as antiviral.  The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.; Sender's Comments: Vaccine efficacy varies from person to person and is affected by many factors. The association between the event drug ineffective (CoVID-19) with the suspect product BNT162B2 OMI XBB.1.5 cannot be fully excluded.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Vaccination failure
Clinical narrative: COVID 19; COVID 19 Treatment; This is a spontaneous report received from a Nurse.  A 67-year-old female patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 10Oct2023 at 12:00 as dose 1, single (Lot number: HF9300) at the age of 67 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Graves' disease" (unspecified if ongoing); "HTN" (unspecified if ongoing). The patient had no known allergies.The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant) with onset Feb2024, outcome "unknown", described as "COVID 19"; COVID-19 (medically significant) with onset Feb2024, outcome "unknown", described as "COVID 19 Treatment". Therapeutic measures were taken as a result of vaccination failure, covid-19. The patient was given nirmatrelvir, ritonavir (PAXLOVID) as treatment of COVID-19 starting on 25Feb2024 until 07Mar2024.  No follow-up attempts are possible.; Sender's Comments: A causal relationship to the suspect drug BNT162B2 OMI XBB.1.5 cannot be excluded for event vaccination failure. This case will be reassessed upon receipt of additional information.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, Interchange of vaccine products, SARS-CoV-2 test
Clinical narrative: COVID 19; COVID 19; Pfizer=01Jun2023 /Moderna=25Sep2023; This is a spontaneous report received from a Consumer or other non HCP.  An 80-year-old male patient received BNT162b2 (BNT162B2 NOS), on 01Jun2023 as dose number unknown, single (Batch/Lot number: unknown) at the age of 79 years, in left arm for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 25Sep2023 as dose number unknown, single), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Metastatic prostate cancer" (unspecified if ongoing); "Known allergies: Sulfa drugs" (unspecified if ongoing). Concomitant medication(s) included: DAROLUTAMIDE, start date: 12Sep2023, stop date: 24Feb2024. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 25Sep2023, outcome "unknown", described as "Pfizer=01Jun2023 /Moderna=25Sep2023"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 21Feb2024, outcome "recovered" (01Mar2024) and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (01Mar2024) Negative, notes: Rebound. Neg on day 10, pos on days 12 and 14; (03Mar2024) Positive, notes: Rebound. Neg on day 10, pos on days 12 and 14; (05Mar2024) Positive, notes: Rebound. Neg on day 10, pos on days 12 and 14. Therapeutic measures were taken as a result of drug ineffective, covid-19. Anti-viral details: Paxloid, from 25Feb2024 till 29Feb2024 for treatment of COVID-19.  Clinical course: Other medication in 2 weeks.   No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Age: 35.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: COVID 19; COVID 19; This is a spontaneous report received from a Consumer or other non HCP.  A 36-year-old female patient (not pregnant) received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), on 13Oct2023 as dose 1, single (Lot number: Hg2282) at the age of 35 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "known allergies: Tree nuts" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: janssen (DOSE 1; lot number: 202a21a; in left arm), administration date: 08Apr2021, when the patient was 33-year-old, for COVID-19 Immunization; BNT162b2 (DOSE 2; lot number: Fh8028; in left arm), administration date: 20Nov2021, when the patient was 33-year-old, for COVID-19 Immunization; BNT162b2;BNT162b2 omi ba.4-5 (DOSE 3 (BOOSTER); lot number: Gh9694; in left arm), administration date: 09Sep2022, when the patient was 34-year-old, for COVID-19 Immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 26Feb2024, outcome "not recovered" and all described as "COVID 19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (26Feb2024) Positive, notes: Original COVID positive on evening of 26Feb2024. Therapeutic measures were taken as a result of vaccination failure, covid-19. The patient received PAXLOVID as COVID-19 treatment from 27Feb2024 to 02Mar2024.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400059944 Same patient, different dose and event;US-PFIZER INC-202400059503 Same patient, different product and event;
Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: 3 patients contracted Covid-19 after receiving the Pfizer Covid-19 vaccination; 3 patients contracted Covid-19 after receiving the Pfizer Covid-19 vaccination; This is a spontaneous report received from an Other HCP. Other Case identifier(s): MOD-2024-762563, MOC20240305000013.  A patient (age and gender not provided) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 04Mar2024, outcome "not recovered" and all described as "3 patients contracted Covid-19 after receiving the Pfizer Covid-19 vaccination".  No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.; Sender's Comments: Based on the information currently available, a lack of efficacy with BNT162B2 in this patient cannot be completely excluded.  ,Linked Report(s) : US-PFIZER INC-PV202400032752 same reporter/drug/event, different patient;US-PFIZER INC-202400059978 same reporter/drug/event, different patient;
Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: 3 patients contracted Covid-19 after receiving the Pfizer Covid-19 vaccination; 3 patients contracted Covid-19 after receiving the Pfizer Covid-19 vaccination; This is a spontaneous report received from an Other HCP. Other Case identifier(s): MOD-2024-762563, MOC20240305000013.  A patient (age and gender not provided) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 04Mar2024, outcome "not recovered" and all described as "3 patients contracted Covid-19 after receiving the Pfizer Covid-19 vaccination".   No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.; Sender's Comments: Vaccine efficacy varies from person to person and is affected by many factors. The association between the event drug ineffective (CoVID-19) with the suspect product BNT162B2 cannot be fully excluded.,Linked Report(s) : US-PFIZER INC-PV202400032752 same reporter/drug/event, different patient;US-PFIZER INC-202400059977 same reporter/drug/event, different patient;
Age: 50.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID-19; COVID-19; This is a spontaneous report received from a Nurse.  A 51-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 05Oct2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 50 years for covid-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single), as dose 2, single) and as dose 3 (booster), single) for covid-19 immunisation. The patient's relevant medical history included: "Obesity" (unspecified if ongoing); "osteoarthritis" (unspecified if ongoing); "depression" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Augmentin, reaction(s): "Drug allergies: Augmentin". The following information was reported: COVID-19 (medically significant), DRUG INEFFECTIVE (medically significant), outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: positive. Therapeutic measures were taken as a result of covid-19, drug ineffective with Paxlovid from 24Feb2024 to 29Feb2024.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 will be requested and submitted if and when received.; Sender's Comments: The causal association of reported event drug ineffective with associated event COVID 19 in relation to suspected vaccine BNT162b2, BNT162b2 omi ba.4-5 is porbably related based on temporal relation and observed clinical outcome after the suspected drug was administered.
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: Had every Pfizer COVID shot and up to date Booster, still spouse and I got it and it was bad; Had every Pfizer COVID shot and up to date Booster, still spouse and I got it and it was bad; This is a spontaneous report received from a Consumer or other non HCP.  A 71-year-old male patient received BNT162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (Primary Immunization series complete, unknown manufacture), for COVID-19 Immunization; Bnt162b2;bnt162b2 omi ba.4-5 (Dose number unknown (Booster), Single), for COVID-19 Immunization. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Jan2024, outcome "unknown" and all described as "Had every Pfizer COVID shot and up to date Booster, still spouse and I got it and it was bad". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: Had every Pfizer COVID shot and up to date Booster, still spouse and I got it and it was bad. COVID 08Jan2024 last dose 13Jan2024 rebound (very sick) 16Jan2024 includes 4 days worst diarrhea ever had.  The information on the batch/lot number for BNT162b2 omi xbb.1.5 will be requested and submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202400058680 Same reporter/drug/event, different patient;
Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective
Clinical narrative: 3 patients contracted Covid-19 after receiving the Pfizer Covid-19 vaccination; 3 patients contracted Covid-19 after receiving the Pfizer Covid-19 vaccination; This is a spontaneous report received from an Other HCP. Other Case identifier(s): MOD-2024-762563, MOC20240305000013.  A patient (age and gender not provided) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 04Mar2024, outcome "not recovered" and all described as "3 patients contracted Covid-19 after receiving the Pfizer Covid-19 vaccination".  No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.; Sender's Comments: Vaccine efficacy varies from person to person and is affected by many factors. The association between the event drug ineffective (CoVID-19) with the suspect product BNT162B2 cannot be fully excluded.,Linked Report(s) : US-PFIZER INC-202400059977 same reporter/drug/event, different patient;US-PFIZER INC-202400059978 same reporter/drug/event, different patient;
Sex: U
Vaccine: COVID19
Symptoms: COVID-19, Drug ineffective, Interchange of vaccine products, SARS-CoV-2 test
Clinical narrative: tested positive for covid; tested positive for covid; 4th: Pfizer 04Oct2022/Interchange of vaccine products; This is a spontaneous report received from an Other HCP. Other Case identifier(s): MOD-2024-760163.  A patient (age and gender not provided) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 04Oct2022 as dose 4 (booster), single (Lot number: GJ5342) for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), on 02Dec2021 as dose 2 (booster), single) and on 29Apr2022 as dose 3 (booster), single) for covid-19 immunisation; COVID-19 vaccine nrvv ad26 (jnj 78436735) (JANSSEN COVID-19 VACCINE), in 2021 as dose 1, single) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 04Oct2022, outcome "recovered", described as "4th: Pfizer 04Oct2022/Interchange of vaccine products"; DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 13Oct2023, outcome "recovered" and all described as "tested positive for covid". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (13Oct2023) Positive. Clinical course: HCP called 09Feb2024 at 5:18pm and explained that they were travelling and they were up to date on their covid vaccinations. Once they got to (withheld) last year and they were there for approximately one month and a half, tested positive for covid (13Oct2023) after receiving the Pfizer vaccine in 2022.; Sender's Comments: Vaccine efficacy varies from person to person and is affected by many factors. The association between the event drug ineffective (CoVID-19) with the suspect product BNT162B2, BNT162B2 OMI BA.4-5 cannot be fully excluded.
Sex: U
Vaccine: COVID19
Symptoms: Dizziness, General physical health deterioration, Malaise, Syncope
Clinical narrative: fainted at home; fell ill; dizziness; health declined; This is a spontaneous report received from a Consumer or other non HCP, Program ID  A patient (age and gender not provided) received BNT162b2 (BNT162B2), in Aug2021 as dose 1, single (Batch/Lot number: unknown) and in Oct2021 as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: SYNCOPE (medically significant), outcome "unknown", described as "fainted at home"; MALAISE (non-serious), outcome "unknown", described as "fell ill"; DIZZINESS (non-serious), outcome "unknown"; GENERAL PHYSICAL HEALTH DETERIORATION (non-serious), outcome "unknown", described as "health declined". The events "fainted at home", "fell ill", "dizziness" and "health declined" required physician office visit. Clinical course: Patient received Pfizer Covid 19 shot in Aug and Oct2021 and patient immediately felt ill. Instant dizziness and fainted at home. Then patient health declined. Patient had a year full of health records from hospitals and rehab centers and patient asked for the protocol that patient can follow for being vaccine injured.  The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.
Sex: U
Vaccine: COVID19
Symptoms: Arthritis, X-ray limb abnormal
Clinical narrative: Beginning in the end of 2022, (Current hand Ahtritis got worst)/SinceFeb 2023, both hands are gradually getting worse and feeling more pain; This is a spontaneous report received from a Consumer or other non HCP. Other Case identifier(s): MOD-2023-734049 (Moderna).  A patient (age and gender not provided) received BNT162b2 (BNT162B2), on 09May2022 as dose 4 (booster), single (Lot number: FM9992) for covid-19 immunisation. The patient's relevant medical history included: "hand Arthritis", start date: 2016 (ongoing), notes: Initially diagnosed with arthritis on the left joint in 2016 and no symptoms in other parts of body. The patient's concomitant medications were not reported. Vaccination history included: moderna COVID-19 vaccine (dose 3, Lot 066F21A), administration date: 02Nov2021, for Covid-19 immunisation; moderna COVID-19 vaccine (dose 2, Lot 011A21A), administration date: 04Mar2021, for Covid-19 immunisation; moderna COVID-19 vaccine (dose 1, Lot 029L20A), administration date: 03Feb2021, for Covid-19 immunisation. The following information was reported: ARTHRITIS (non-serious) with onset 2022, described as "Beginning in the end of 2022, (Current hand Ahtritis got worst)/SinceFeb 2023, both hands are gradually getting worse and feeling more pain". The events "beginning in the end of 2022, (current hand ahtritis got worst)/sincefeb 2023, both hands are gradually getting worse and feeling more pain" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Additional information: It was reported that in the end of 2022, current hand arthritis got worst, and needed to visit physician. Since prior to 2022 right hand exhibited no symptoms. Since Feb-2023, both hands are gradually getting worse and feeling more pain. Consumer cited condition where was initially diagnosed with arthritis on the left joint in 2016 and no symptoms in other parts of body but in Jan of 2022, right hand joint began to hurt. Thought it was some kind of injury that will get well but it got worse. Consulted with a doctor and x-ray of right thumb revealed no cartilage in between the bones, it was "bone on bone". states that the "cartilage in hands is now gone. The pain was constant and chronic. Was wondering if the mRNA vaccine had contributed to the worsening of arthritis.
Sex: F
Vaccine: FLU4
Symptoms: Illness, Influenza, Malaise
Clinical narrative: his wife got sick with the flu last Sunday; She ended up getting hospitalized and was seriously ill; Initial information was received on 04-Mar-2024 regarding an unsolicited valid  serious case received from patient husband.  This case is linked to case 2024SA074875.  This case involves an unknown age female patient who experienced his wife got sick with the flu last sunday and she ended up getting hospitalized and was seriously ill after receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   In October 2023, the patient received a  dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (dose, formulation, strength, and expiry date: unknown) via unknown route in unknown administration site for prophylactic vaccination (immunization).  On an unknown date the patient developed a serious his wife got sick with the flu last sunday (influenza) and she ended up getting hospitalized and was seriously ill (illness) (unknown latency).  Reportedly:- It provided no protection no effectiveness whatsoever. His wife is currently out of the hospital but is still on several medications. After that he then got the flu from his wife. He started to not feel well. He said he was in generally in good health prior to him getting the flu. He described that the vaccine hardly touched them and that it was ineffective.   Action taken: not applicable.  Corrective:She had to be put on oxygen, and was high doses of corticosteroids, antibiotics   At time of reporting, the outcome was Unknown for both events.  Seriousness criteria: hospitalization for both events
Age: 18.0
Sex: F
Vaccine: COVID19-2, FLU4
Symptoms: Extra dose administered
Clinical narrative: Patient got two doses of Covid Vaccine and Fluzone.
Age: 37.0
Sex: F
Vaccine: COVID19, FLU4
Symptoms: Bacterial test positive, Cold sweat, Contusion, Cyanosis, Dizziness
Clinical narrative: Patient was seen leaning on the wall by the nurse's station and started to fall on the floor. She was observed very pale and mute, with circumoral cyanosis. Initial VS: BP 98/61 P 67/min RR 22/min O2 Sat 98% Temp 97%. Patient is oriented to time, place, person, situation. Glasgow coma scale 15. MD evaluated patient who started to become dizzy again, skin cold and clammy, looks very pale, VS at 0528 64/40, O2 Sat 98%. Patient is transferred to QVMC for further evaluation of loss of consciousness, hypotension.  Discharge from hospital QVMC diagnosis: Syncope, Vasovagal; Contusion of Left Upper Extremity.
Age: 37.0
Sex: F
Vaccine: COVID19, FLU4
Symptoms: Fall, Full blood count normal, Hypotension, Loss of consciousness, Metabolic function test normal
Clinical narrative: Patient was seen leaning on the wall by the nurse's station and started to fall on the floor. She was observed very pale and mute, with circumoral cyanosis. Initial VS: BP 98/61 P 67/min RR 22/min O2 Sat 98% Temp 97%. Patient is oriented to time, place, person, situation. Glasgow coma scale 15. MD evaluated patient who started to become dizzy again, skin cold and clammy, looks very pale, VS at 0528 64/40, O2 Sat 98%. Patient is transferred to QVMC for further evaluation of loss of consciousness, hypotension.  Discharge from hospital QVMC diagnosis: Syncope, Vasovagal; Contusion of Left Upper Extremity.
Age: 37.0
Sex: F
Vaccine: COVID19, FLU4
Symptoms: Mutism, Pallor, Red blood cells urine positive, Syncope, Urine analysis abnormal
Clinical narrative: Patient was seen leaning on the wall by the nurse's station and started to fall on the floor. She was observed very pale and mute, with circumoral cyanosis. Initial VS: BP 98/61 P 67/min RR 22/min O2 Sat 98% Temp 97%. Patient is oriented to time, place, person, situation. Glasgow coma scale 15. MD evaluated patient who started to become dizzy again, skin cold and clammy, looks very pale, VS at 0528 64/40, O2 Sat 98%. Patient is transferred to QVMC for further evaluation of loss of consciousness, hypotension.  Discharge from hospital QVMC diagnosis: Syncope, Vasovagal; Contusion of Left Upper Extremity.
Age: 37.0
Sex: F
Vaccine: COVID19, FLU4
Symptoms: White blood cells urine positive, X-ray limb normal
Clinical narrative: Patient was seen leaning on the wall by the nurse's station and started to fall on the floor. She was observed very pale and mute, with circumoral cyanosis. Initial VS: BP 98/61 P 67/min RR 22/min O2 Sat 98% Temp 97%. Patient is oriented to time, place, person, situation. Glasgow coma scale 15. MD evaluated patient who started to become dizzy again, skin cold and clammy, looks very pale, VS at 0528 64/40, O2 Sat 98%. Patient is transferred to QVMC for further evaluation of loss of consciousness, hypotension.  Discharge from hospital QVMC diagnosis: Syncope, Vasovagal; Contusion of Left Upper Extremity.
Age: 74.0
Sex: M
Vaccine: VARZOS
Symptoms: Injection site pain, Injection site reaction, Musculoskeletal stiffness
Clinical narrative: Sore arm, muscle stiffness lasting for 3 months after the injection at the injection site.
Age: 1.58
Sex: M
Vaccine: MMRV
Symptoms: No adverse event, Wrong product administered
Clinical narrative: MMRV was inadvertently co-administered with Varicella instead of MMR as ordered.  Family informed of error.  Child has no adverse effects appreciable at this time.  Mom informed of increased risk of systemic or local reaction, fever, febrile seizure, etc
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Cough, Dyspnoea, SARS-CoV-2 test positive
Clinical narrative: Patient stated she started coughing  a few days after receiving vaccine on 1/22/24 and has not stopped coughing ever since; also tested positive for Covid-19 a week after on 1/29/24; has also been having shortness of breath
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Electrocardiogram ambulatory, Myocardial ischaemia, Transient ischaemic attack
Clinical narrative: TIAs 7/24/21 and 8/3/21. Prior cardiac imaging clear until Aug 2022, myocardial ischemia noted on cardiac MRI during workup for amyloid to rule out cardiac amyloid involvement. Led dr to believe I did have cardiac Amyloidosis when mutation is suspected to be neuropathic form. Next cMRI done Sept 2023 totally clear, not amyloid. Dr unable to tell me why I had irreversible tissue damage in my heart that suddenly cleared up.
Age: 20.0
Sex: F
Vaccine: FLU4, HEP, TDAP
Symptoms: Blood glucose, Injury associated with device
Clinical narrative: NEEDLE STICK INJURY
Age: 72.0
Sex: M
Vaccine: HEPAB, PNC20, RSV
Symptoms: Chromaturia
Clinical narrative: patient states has dark colored (rust colored) urine started 1 day following immunization. he states it is now improving 2 days later and urine is not as dark
Age: 56.0
Sex: F
Vaccine: TDAP
Symptoms: Antinuclear antibody positive, Arthralgia, Asthenia, Groin pain, Inflammatory marker test
Clinical narrative: I had the normal tetanus side effects until the evening of January 18th. I had pain in my left groin and knee that was a 10/10 . Almost went to the ER. I have have been recovering from a fractured femoral head and working to regain my mobility. The side effect seemed to attack the weakest parts of my body. I was incapicitated. When reported to health, both said it's "weird" and told me to take OTC pain relievers. It is now almost 2-month later and I still have significant pain and have lost significant range of motion.
Age: 56.0
Sex: F
Vaccine: TDAP
Symptoms: Joint range of motion decreased, Magnetic resonance imaging normal, Mobility decreased, Pain
Clinical narrative: I had the normal tetanus side effects until the evening of January 18th. I had pain in my left groin and knee that was a 10/10 . Almost went to the ER. I have have been recovering from a fractured femoral head and working to regain my mobility. The side effect seemed to attack the weakest parts of my body. I was incapicitated. When reported to health, both said it's "weird" and told me to take OTC pain relievers. It is now almost 2-month later and I still have significant pain and have lost significant range of motion.
Age: 50.0
Sex: F
Vaccine: TDAP, VARZOS
Symptoms: Headache, Injection site erythema, Injection site pruritus, Injection site rash, Injection site swelling
Clinical narrative: Headaches, slight swelling and redness at infection site 1 day after shot lasting 5 days. Day 6, the entire upper arm swelled with several rash areas, redness, hot to touch, and itching. Pharmacist said it's commom to have shingles side effects for up to one month after shot?
Age: 50.0
Sex: F
Vaccine: TDAP, VARZOS
Symptoms: Injection site warmth
Clinical narrative: Headaches, slight swelling and redness at infection site 1 day after shot lasting 5 days. Day 6, the entire upper arm swelled with several rash areas, redness, hot to touch, and itching. Pharmacist said it's commom to have shingles side effects for up to one month after shot?
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Acute myocardial infarction, Arteriogram coronary abnormal, Arteriosclerosis, Arthralgia, COVID-19
Clinical narrative: PFIZER #1 3/30/2021 PFIZER #2 4/20/2021 PFIZER #3 1/10/2022 PATIENT DEVELOPED SEVERE HYPERTENSION AND CHEST PAIN AFTER THE THIRD SHOT AND WAS HOSPITALIZED MULTIPLE TIMES FOR BLOOD PRESSURE CONTROL AND TO RULE OUT MYOCARDIAL INFARCTION.  WORKING DIAGNOSIS WAS COVID-19 VACCINE ACCLERATED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE.   2023 HE UNDERWENT ANGIOGRAPHY FOR ACUTE MI AND UNDERWENT ADDITIONAL CORONARY STENTING.  HE WAS LEFT WITH ISCHEMIC CARDIOMYOPATHY AND LV DYSFUNCTION LVEF 50%.  HE ALSO DEVELOPED POST EXERTIONAL FATIGUE, ARTHRALGIAS, AND MYALGIAS.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Chest pain, Condition aggravated, Coronary arterial stent insertion, Echocardiogram, Ejection fraction decreased
Clinical narrative: PFIZER #1 3/30/2021 PFIZER #2 4/20/2021 PFIZER #3 1/10/2022 PATIENT DEVELOPED SEVERE HYPERTENSION AND CHEST PAIN AFTER THE THIRD SHOT AND WAS HOSPITALIZED MULTIPLE TIMES FOR BLOOD PRESSURE CONTROL AND TO RULE OUT MYOCARDIAL INFARCTION.  WORKING DIAGNOSIS WAS COVID-19 VACCINE ACCLERATED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE.   2023 HE UNDERWENT ANGIOGRAPHY FOR ACUTE MI AND UNDERWENT ADDITIONAL CORONARY STENTING.  HE WAS LEFT WITH ISCHEMIC CARDIOMYOPATHY AND LV DYSFUNCTION LVEF 50%.  HE ALSO DEVELOPED POST EXERTIONAL FATIGUE, ARTHRALGIAS, AND MYALGIAS.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Electrocardiogram, Fatigue, Hypertension, Ischaemic cardiomyopathy, Laboratory test
Clinical narrative: PFIZER #1 3/30/2021 PFIZER #2 4/20/2021 PFIZER #3 1/10/2022 PATIENT DEVELOPED SEVERE HYPERTENSION AND CHEST PAIN AFTER THE THIRD SHOT AND WAS HOSPITALIZED MULTIPLE TIMES FOR BLOOD PRESSURE CONTROL AND TO RULE OUT MYOCARDIAL INFARCTION.  WORKING DIAGNOSIS WAS COVID-19 VACCINE ACCLERATED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE.   2023 HE UNDERWENT ANGIOGRAPHY FOR ACUTE MI AND UNDERWENT ADDITIONAL CORONARY STENTING.  HE WAS LEFT WITH ISCHEMIC CARDIOMYOPATHY AND LV DYSFUNCTION LVEF 50%.  HE ALSO DEVELOPED POST EXERTIONAL FATIGUE, ARTHRALGIAS, AND MYALGIAS.
Age: 66.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Left ventricular dysfunction, Myalgia
Clinical narrative: PFIZER #1 3/30/2021 PFIZER #2 4/20/2021 PFIZER #3 1/10/2022 PATIENT DEVELOPED SEVERE HYPERTENSION AND CHEST PAIN AFTER THE THIRD SHOT AND WAS HOSPITALIZED MULTIPLE TIMES FOR BLOOD PRESSURE CONTROL AND TO RULE OUT MYOCARDIAL INFARCTION.  WORKING DIAGNOSIS WAS COVID-19 VACCINE ACCLERATED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE.   2023 HE UNDERWENT ANGIOGRAPHY FOR ACUTE MI AND UNDERWENT ADDITIONAL CORONARY STENTING.  HE WAS LEFT WITH ISCHEMIC CARDIOMYOPATHY AND LV DYSFUNCTION LVEF 50%.  HE ALSO DEVELOPED POST EXERTIONAL FATIGUE, ARTHRALGIAS, AND MYALGIAS.
Age: 64.0
Sex: F
Vaccine: TD
Symptoms: Hypoaesthesia, Musculoskeletal stiffness, Paraesthesia
Clinical narrative: She developed tingling and numbness going up right neck and side of face and posterior to the ear, then began to have same sensation on the left side and then felt stiff in her neck.  She was advised to drink plenty of water and take ibuprofen. She was given ER precautions for trouble with breathing or overall worsening of condition.